Freedom Capital Markets has lowered its price target for Li Auto (NASDAQ: LI) from $34 to $25, citing a mixed quarterly performance and a challenging outlook as China's electric vehicle sector grapples with a fierce price war and softening demand.
Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.
While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
UBS has increased its price target for digital transformation leader Globant to $75, forecasting a period of stabilized, if modest, growth for the IT services sector next year despite near-term revenue headwinds.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Despite a recent price target cut by KeyBanc, On Holding AG (NYSE: ONON) remains a top growth pick for 2026, with Goldman Sachs upgrading the stock to Buy. Analysts highlight the brand's global momentum and product strength as key drivers.
Truist Securities has raised its price target for Amer Sports (NYSE: AS), citing the company's clear long-term roadmap and 'durable growth levers' across its portfolio of iconic sports brands. The firm sees a realistic path to earnings per share exceeding $2.50 by fiscal 2030.
Despite a recent 6.8% pullback, AUTO1 Group SE (ETR:AG1) has delivered a staggering 239% return to its shareholders over the past three years, highlighting the potential rewards of holding through market volatility. We examine the underlying business trends and investor sentiment behind the numbers.
As the FTSE indices reel from weak Chinese trade data, a screen of undervalued UK equities reveals potential opportunities. We examine three companies trading significantly below their estimated cash flow value.
With key self-assessment deadlines approaching, property investors must navigate a changed landscape of tax reliefs and allowable expenses to minimise their liabilities. Experts urge early preparation to avoid costly surprises.
With the annual self-assessment deadline a perennial source of stress for freelancers and sole traders, this guide breaks down the essentials of income tax and National Insurance. The landscape is set for a significant shift with the incoming Making Tax Digital regime, making this a crucial year to get to grips with the current rules.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
Buoyed by record bookings and strong financial performance in 2025, Royal Caribbean Group projects double-digit revenue growth for 2026. The cruise giant announced a major fleet expansion, including a new 'Discovery Class' and ten additional river cruise ships, signaling confidence in sustained consumer appetite for experiential travel.
As global economic headwinds persist, UK investors are turning to dividend-paying stocks for portfolio resilience. We analyze three FTSE-listed companies with strong income credentials and growth potential for the coming year.
A sharp downturn in Bitcoin triggered a massive $1.7 billion liquidation event over 24 hours, with leveraged long positions bearing the brunt of the sell-off as market sentiment shifted.
PennyMac Mortgage Investment Trust (PMT) closed 2025 with robust earnings, driven by a dramatic expansion in its private-label securitization business. While this growth fueled returns, the company's correspondent lending segment faced pressure, and faster mortgage prepayments impacted servicing rights income.
